NEW YORK, May 15 – Beyond Genomics said Tuesday it has entered its first corporate partnership, penning a deal with Elan Pharmaceuticalsto apply its systems biology techniques for Alzheimer's research.

In exchange for Beyond Genomics’ two-year commitment to the program, during which the companies will seek to find biomarkers and drug targets for Alzheimer's disease, Elan made a $5 million equity investment in the company.

Beyond Genomics did not disclose any more financial details.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.